KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Debt: 2010-2024

Historic Non-Current Debt for Pacira BioSciences (PCRX) over the last 7 years, with Dec 2024 value amounting to $383.5 million.

  • Pacira BioSciences' Non-Current Debt rose 252.00% to $376.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.7 million, marking a year-over-year increase of 252.00%. This contributed to the annual value of $383.5 million for FY2024, which is 232.93% up from last year.
  • Per Pacira BioSciences' latest filing, its Non-Current Debt stood at $383.5 million for FY2024, which was up 232.93% from $115.2 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Non-Current Debt registered a high of $383.5 million during FY2024, and its lowest value of $115.2 million during FY2023.
  • Over the past 3 years, Pacira BioSciences' median Non-Current Debt value was $251.1 million (recorded in 2022), while the average stood at $249.9 million.
  • Per our database at Business Quant, Pacira BioSciences' Non-Current Debt plummeted by 54.11% in 2023 and then surged by 232.93% in 2024.
  • Over the past 4 years, Pacira BioSciences' Non-Current Debt (Yearly) stood at $335.3 million in 2021, then declined by 25.12% to $251.1 million in 2022, then slumped by 54.11% to $115.2 million in 2023, then surged by 232.93% to $383.5 million in 2024.